|
UK physician revolutionizes gene research
March 27, 2008A dramatic new study published in the most recent issue of Nature questions some of the mechanisms underlying a new class of drugs based on Nobel Prize-winning work designed to fight diseases ranging from macular degeneration to diabetes.
Dr. Jayakrishna Ambati, a University of Kentucky researcher and the paper's senior author, has for years been investigating gene silencing, a 1998 discovery that won a Nobel Prize in Physiology or Medicine in unusually quick fashion in 2006.
While the prize-winning discovery remains important, the findings made by Ambati's lab show the mechanisms behind it are not as scientists once believed. In fact, Ambati's work imparts the need for caution in current clinical trials using the technology, as it may have potentially harmful effects on subjects.
Gene Silencing Leads to New Class of Drugs
In short, researchers in 1998 discovered a class of double-stranded RNA (dsRNA) that possessed powerful gene-silencing capabilities, or the ability to "turn off" disease-causing genes in the body.
The technique of targeting these dsRNA for single genes was refined with synthetic molecules called small-interfering RNA (siRNA). siRNA were thought to have the capability to interfere with specific disease-causing genes and prevent them from being expressed.
Because gene-targeted silencing with siRNA does not involve permanent DNA mutations, this approach rapidly gained popularity throughout biomedical research. The breakthrough, with the powerful ability to turn off genes, has become a standard research tool for genetic studies and has resulted in a new class of 21st century drugs designed to silence disease-causing genes in the body or disarm an invading virus by knocking out its genes.
Many diseases including age-related macular degeneration, diabetes, kidney disease, cancer, Lou Gehrig's and Parkinson's have been heralded as candidates for siRNA therapy, creating a wave of on-going clinical trials.
New Discovery Shows Therapies Could Have Harmful Side Effects
Ambati, professor and vice chair of ophthalmology and visual sciences at the University of Kentucky College of Medicine, and his colleagues have made a critical discovery that challenges the view that siRNA's therapeutic effects are imparted solely through RNA interference.
Ambati and collaborators argue that siRNA functions generically rather than specifically, thus the new class of drugs being formulated may actually adversely affect blood vessel growth in a variety of organs.
"siRNAs are used in every area of biomedical research and are thought to be exquisitely specific in targeting a single gene," Ambati said. "My lab made the surprising discovery that siRNAs, including those in clinical trials, do not enter cells or trigger RNAi. Rather, we found that they generically, regardless of their sequence or target, bind a receptor known as TLR3 on cell surfaces and block blood vessel growth in the eye, skin and a variety of other organs."
Blocking blood vessel growth is beneficial in a variety of diseases. Prime examples include wet AMD, an eye disease hallmarked by the abnormal growth of blood vessels beneath the retina, as well as cancer. However, blocking blood vessel growth by administering siRNA intravenously could be detrimental if it impacts other organs, according to Ambati's study.
Ambati, however, quickly notes the Nobel Prize-winning discovery is still valid.
"RNA interference does, of course, exist," said Ambati, a University Research Professor and the Dr. E. Vernon Smith & Eloise C. Smith Endowed Chair in Macular Degeneration Research. "It is just that siRNA functions differently than commonly believed - not via RNA interference."
Ambati said the main implications of his research are two fold:
1. for researchers to understand how siRNAs actually work
2. for clinical trials of siRNA to be approached with great caution.
Ambati's lab also showed that people with a mutation in the TLR3 receptor would be resistant to the generic effects of siRNAs, thereby providing hope for personalized medicine in this population.
The next steps, Ambati said, are to better understand the generic mechanism of siRNA that inhibits blood vessel growth and to discover how to render it useful in creating treatments for the many conditions that would benefit from such effects. His lab also will work to refine siRNAs to potentially achieve their promise of precise gene targeting.
University of Kentucky
Gene Silencing Leads to New Class of Drugs
In short, researchers in 1998 discovered a class of double-stranded RNA (dsRNA) that possessed powerful gene-silencing capabilities, or the ability to "turn off" disease-causing genes in the body.
The technique of targeting these dsRNA for single genes was refined with synthetic molecules called small-interfering RNA (siRNA). siRNA were thought to have the capability to interfere with specific disease-causing genes and prevent them from being expressed.
Because gene-targeted silencing with siRNA does not involve permanent DNA mutations, this approach rapidly gained popularity throughout biomedical research. The breakthrough, with the powerful ability to turn off genes, has become a standard research tool for genetic studies and has resulted in a new class of 21st century drugs designed to silence disease-causing genes in the body or disarm an invading virus by knocking out its genes.
Many diseases including age-related macular degeneration, diabetes, kidney disease, cancer, Lou Gehrig's and Parkinson's have been heralded as candidates for siRNA therapy, creating a wave of on-going clinical trials.
New Discovery Shows Therapies Could Have Harmful Side Effects
Ambati, professor and vice chair of ophthalmology and visual sciences at the University of Kentucky College of Medicine, and his colleagues have made a critical discovery that challenges the view that siRNA's therapeutic effects are imparted solely through RNA interference.
Ambati and collaborators argue that siRNA functions generically rather than specifically, thus the new class of drugs being formulated may actually adversely affect blood vessel growth in a variety of organs.
"siRNAs are used in every area of biomedical research and are thought to be exquisitely specific in targeting a single gene," Ambati said. "My lab made the surprising discovery that siRNAs, including those in clinical trials, do not enter cells or trigger RNAi. Rather, we found that they generically, regardless of their sequence or target, bind a receptor known as TLR3 on cell surfaces and block blood vessel growth in the eye, skin and a variety of other organs."
Blocking blood vessel growth is beneficial in a variety of diseases. Prime examples include wet AMD, an eye disease hallmarked by the abnormal growth of blood vessels beneath the retina, as well as cancer. However, blocking blood vessel growth by administering siRNA intravenously could be detrimental if it impacts other organs, according to Ambati's study.
Ambati, however, quickly notes the Nobel Prize-winning discovery is still valid.
"RNA interference does, of course, exist," said Ambati, a University Research Professor and the Dr. E. Vernon Smith & Eloise C. Smith Endowed Chair in Macular Degeneration Research. "It is just that siRNA functions differently than commonly believed - not via RNA interference."
Ambati said the main implications of his research are two fold:
1. for researchers to understand how siRNAs actually work
2. for clinical trials of siRNA to be approached with great caution.
Ambati's lab also showed that people with a mutation in the TLR3 receptor would be resistant to the generic effects of siRNAs, thereby providing hope for personalized medicine in this population.
The next steps, Ambati said, are to better understand the generic mechanism of siRNA that inhibits blood vessel growth and to discover how to render it useful in creating treatments for the many conditions that would benefit from such effects. His lab also will work to refine siRNAs to potentially achieve their promise of precise gene targeting.
University of Kentucky
Gene Research News and Current Gene Research Events RSSResearchers urge ethics guidelines for human-genome research
A global team of legal, scientific and ethics experts have put forward eight key recommendations to establish much needed guidelines for conducting human-genome sequencing research.
Leading researchers to reveal comprehensive dos and don'ts for prostate cancer
Today at the Prostate Cancer Foundation's Annual Scientific Retreat, researchers will share new findings on how eating common foods such as tomatoes and fish, maintaining a healthy weight, and avoiding meats cooked at high temperatures may help prevent prostate cancer, and help men live healthier and longer after diagnosis.
Does a producer benefit from research?
ISAE Helsinki 2004 Information bulletin August 4, 2004 Does a producer benefit from research? In the view of professor Per Jensen, an ethologist at Linköping University in Sweden and one of the world's leading experts on animal behaviour, Nordic animal welfare research is of a high standard and is focused on scientifically relevant issues. However, according to Jensen, more basic research and new evaluation methods are needed, and in his opinion gene research combined with behavioural research could in particular provide new tools for this purpose. Breeding choices made in the past few decades have mainly helped to bring about a dramatic increase in production. However, these choices may al
EU 'Newmood' research investigating genetic links to treat depression with new drugs
120 million people worldwide suffer from depression. An EU-funded research project launched recently will help to uncover the genetic factors linked to depression to develop new drug treatments. The Integrated Project, named NEWMOOD, has received EUR7.2 million in funding from the EU's Sixth Research Framework Programme (FP6) and aims to identify genes involved in triggering depression. This will help researchers to develop new drugs over the next five years to treat it and improve understanding of its causes. The drugs are set to revolutionise antidepressant drugs, which have not changed much over the past 30 years. The project, co-ordinated by the University of Manchester (United Kingdom)
Genes of autumn leaves mapped
It is not known what genes turn leaves yellow in the fall. However, scientists at Ume'å Plant Science Center, Ume'å University, and the Royal Institute of Technology in Stockholm (KTH) have managed to identify more than 2,400 genes that take part in the process. One of the most magnificent pageants of nature every year is when trees take on their autumn colors. Scientists have long known that these colors appear when the green pigment chlorophyll is broken down at the same time as the yellow carotenoids remain and red antocyanines are formed. This process is steered, like all others in a living organism, by genes. Certain genes see to it that the process starts at the right time,
Press Invitation - History And Art Revives Origins Of Genetics In Czech Republic
Artists, scientists, architects and curators from around the world have joined forces with the abbot of the Abbey of St Thomas in Brno, Czech Republic, in a unique venture that honours the father of modern genetics. 'The Genius of Genetics, a celebration of Gregor Mendel through science and art' tells the story of the life and work of the Augustinian friar who, in the 1860s, experimented with peas and discovered the laws that govern heredity. It opens to the public on Tuesday May 21 for one year. The exhibition marks an era in history when gene research is poised to revolutionise medicine - and, already, is relevant to everybody's daily life. It is the first phase of a major initiative to r
Mark McCarthy elected as Robert Turner Professor of Diabetes
- Research centre paves way for 'personalised medicine' in diabetes - Servier endowment will help accelerate gene research in diabetes One of the most prestigious new appointments in the field of diabetes research, the Robert Turner Professorship of Diabetic Medicine, has been announced by the Nuffield Department of Clinical Medicine at the University of Oxford. The new incumbent will be Professor Mark McCarthy, currently Professor of Genomic Medicine at Imperial College, London and Honorary Consultant Physician at St Mary's Hospital. The newly created post, endowed by Servier Laboratories, will be attached to the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), an internat
More Gene Research News Articles
 | Chasing Cool: Standing Out in Today's Cluttered Marketplace by Noah Kerner, Gene Pressman |
 | Mean Genes: From Sex to Money to Food: Taming Our Primal Instincts by Terry Burnham, Jay Phelan |
 | Implementing Change: Patterns, Principles and Potholes (2nd Edition) by Gene E. Hall, Shirley M. Hord |
 | SPSS for Introductory Statistics: Use and Interpretation by George A. Morgan, Nancy L. Leech, Gene W. Gloeckner, Karen C. Barrett |
 | Creating Ever-Cool: A Marketer's Guide to a Kid's Heart by Gene Del Vecchio |
 | Fertilizers, Pills, And Magnetic Strips: The Fate Of Public Education In America (PB) by Gene V Glass |
| Classical education: The movement sweeping America (Studies in Philanthropy) by Gene Edward Veith | |
 | Statistical Methods in Education and Psychology (3rd Edition) by Gene V. Glass, Kenneth D. Hopkins |
 | Coming to Life: How Genes Drive Development by Christiane Nusslein-Volhard |
 | Microarray Gene Expression Data Analysis: A Beginner's Guide by Helen Causton, John Quackenbush, Alvis Brazma |
| © 2008 BrightSurf.com |